A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (NCT07662135)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).
Who can join: Review the eligibility criteria below.
Location: Research Site — Peoria, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (185 Sites)
Showing the first 25 of 185 sites.
- Research Site — Peoria, Arizona
- Research Site — Surprise, Arizona
- Research Site — Concord, California
- Research Site — Sacramento, California
- Research Site — Victorville, California
- Research Site — Fleming Island, Florida
- Research Site — Lauderdale Lakes, Florida
- Research Site — Leesburg, Florida
- Research Site — Miami Lakes, Florida
- Research Site — Ocoee, Florida
- Research Site — Orlando, Florida
- Research Site — Chicago, Illinois
- Research Site — Braintree, Massachusetts
- Research Site — New Bedford, Massachusetts
- Research Site — Worcester, Massachusetts
- Research Site — Saint Joseph, Michigan
- Research Site — Saint Paul, Minnesota
- Research Site — Kansas City, Missouri
- Research Site — Omaha, Nebraska
- Research Site — Las Vegas, Nevada
- Research Site — Albuquerque, New Mexico
- Research Site — The Bronx, New York
- Research Site — Kinston, North Carolina
- Research Site — Raleigh, North Carolina
- Research Site — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 2 Diabetes Mellitus
- Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
- A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Tucson, Arizona
- Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes — Birmingham, Alabama
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Huntsville, Alabama
- GLP-1 and Hypoglycemia — Baltimore, Maryland
Explore by condition: All Type 2 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.